AR029333A1 - Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada - Google Patents
Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinadaInfo
- Publication number
- AR029333A1 AR029333A1 ARP000100507A ARP000100507A AR029333A1 AR 029333 A1 AR029333 A1 AR 029333A1 AR P000100507 A ARP000100507 A AR P000100507A AR P000100507 A ARP000100507 A AR P000100507A AR 029333 A1 AR029333 A1 AR 029333A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- inhibitor
- preparation
- pharmaceutical
- hmgcoa
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 abstract 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 2
- 108010044467 Isoenzymes Proteins 0.000 abstract 2
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 2
- 239000000411 inducer Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
| GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
| GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029333A1 true AR029333A1 (es) | 2003-06-25 |
Family
ID=27269637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100507A AR029333A1 (es) | 1999-02-06 | 2000-02-04 | Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6982157B1 (enExample) |
| EP (1) | EP1185274B1 (enExample) |
| JP (2) | JP2002536331A (enExample) |
| KR (2) | KR20060117381A (enExample) |
| CN (1) | CN1165310C (enExample) |
| AR (1) | AR029333A1 (enExample) |
| AT (1) | ATE282415T1 (enExample) |
| AU (1) | AU767304B2 (enExample) |
| BR (1) | BR0007999A (enExample) |
| CA (1) | CA2358632C (enExample) |
| CZ (1) | CZ301296B6 (enExample) |
| DE (1) | DE60015965T2 (enExample) |
| EE (1) | EE04929B1 (enExample) |
| EG (1) | EG23858A (enExample) |
| ES (1) | ES2232418T3 (enExample) |
| GB (1) | GB0000710D0 (enExample) |
| ID (1) | ID30485A (enExample) |
| IL (1) | IL144715A0 (enExample) |
| IS (1) | IS2337B (enExample) |
| MX (1) | MXPA01007905A (enExample) |
| MY (1) | MY130606A (enExample) |
| NO (1) | NO320745B1 (enExample) |
| NZ (1) | NZ512982A (enExample) |
| PL (1) | PL198034B1 (enExample) |
| PT (1) | PT1185274E (enExample) |
| TR (1) | TR200102228T2 (enExample) |
| TW (1) | TWI282738B (enExample) |
| WO (1) | WO2000045817A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| BRPI0206641B8 (pt) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | uso de um inibidor da absorção de esteróis |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| JP5069001B2 (ja) | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー／エス | フィブラートを含む固体投与形態 |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2005271413A1 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| EP1948600B1 (en) * | 2005-07-05 | 2014-04-16 | The President & Fellows Of Harvard College | Liver targeted conjugates |
| EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
| US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
| CN112955965B (zh) * | 2018-06-14 | 2024-04-09 | 阿斯利康(英国)有限公司 | 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法 |
| US20220273652A1 (en) | 2019-07-31 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| DK0521417T3 (da) * | 1991-07-02 | 1995-03-27 | Benckiser Gmbh Joh A | Sammenklappelig forrådsflaske |
| JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
| FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Ceased
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Ceased
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko not_active Ceased
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 EP EP00901264A patent/EP1185274B1/en not_active Expired - Lifetime
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029333A1 (es) | Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada | |
| AR035500A1 (es) | Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina. | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| BR0007974A (pt) | Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo | |
| DE60115029D1 (de) | Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| AR012614A1 (es) | Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento | |
| CY1109861T1 (el) | Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης | |
| AU2002216701A1 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
| CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| WO2001022791A3 (en) | Controlled release compositions comprising nimesulide | |
| ATE292453T1 (de) | Antivirale arznei | |
| PT1207756E (pt) | Utilizacao de espinosade ou de uma formulacao que compreende espinosade | |
| AU2002214305A1 (en) | Pharmaceutical preparation containing copolyvidone | |
| DE60211139D1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp | |
| WO2002007721A3 (en) | Use of cox-2 inhibitors for preventing immunodeficiency | |
| UY25192A1 (es) | Formulación medicamentosa con liberación controlada de sustancia activa | |
| DE60018629D1 (de) | Carbamazepinformulierung mit verzögerter Freigabe | |
| BR0109747A (pt) | Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática | |
| MXPA04003520A (es) | Formulacion farmaceutica que comprende (r)-bicalutamida. | |
| AR038858A1 (es) | Combinacion | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| HK1040924A1 (zh) | 降膽固醇劑的應用 | |
| SV2002000112A (es) | Complejo farmaceutico ref.pcs10331aksr/bb | |
| WO2005058310A3 (en) | Use of stating for the treatment of metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |